• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ocular Therapeutix shares fall on Q1 miss

May 5, 2017 By Fink Densford

Ocular Therapeutix

Shares in Ocular Therapeutix (NSDQ:OCUL)  fell today after the ophthalmologic device developer posted 1st quarter earnings that missed expectations on Wall Street.

The Bedford, Mass.-based company posted losses of $16 million, or 58¢ per share, on sales of $475,000 for the 3 months ended March 31, seeing losses grow 47.8% while sales grew 14.2% compared with the same period last year.

Losses per share were 10¢ higher than the 48¢ consensus on Wall Street, where analysts were expecting to see sales of $470,000.

“This is an important time for Ocular Therapeutix as we approach the PDUFA target action date for our lead product candidate, Dextenza, for the treatment of ocular pain following ophthalmic surgery. Should Dextenza be approved, its commercial launch will enable our transition into a fully-integrated, commercial-stage, revenue-generating company. Dextenza has now been extensively studied for the treatment of post-surgical ocular pain and inflammation in over 550 clinical trial participants. If approved, we believe Dextenza will address the compliance issues associated with steroid eyedrops and serve as an attractive alternative for both patients and ophthalmologists,” CEO & prez Amar Sawhney said in a press release.

Shares in Ocular Therapeutix have fallen today, down 16.2%, or $1.47, closing at $7.63.

Filed Under: Business/Financial News, Featured, Wall Street Beat Tagged With: Ocular Therapeutix

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS